Assembly Biosciences Inc. (ASMB)
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
5 Stocks With Recent Price Strength Buoyed by a Strong August
EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going
Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Best Momentum Stocks to Buy for August 25th
LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 2026.
New Strong Buy Stocks for August 25th
IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2026.
Best Momentum Stocks to Buy for August 21st
LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.
New Strong Buy Stocks for August 21st
MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.
Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice
Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 40.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
Assembly Biosciences is maintained at a 'Buy' rating, driven by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC, with multiple readouts expected 2027–2028. ASMB's partnership with Gilead on GS-1179 offers strategic optionality between milestone/royalty payments or a 40% cost-profit share.
Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates
Assembly Biosciences (ASMB) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.33 per share a year ago.
